Customer concentration and contract non-renewal
A limited number of Plasma customers account for a material portion of sales, so renewal or pricing changes can quickly affect revenue.
- Scope
- Plasma segment
- Materiality
- high
Haemonetics Corporation
Haemonetics is a U.S.-based medical technology company that designs and sells systems used to collect, process, and manage blood and plasma. Its portfolio spans plasma collection technologies, blood center collection and processing equipment, and hospital products for vascular closure, blood management, and related procedures.
20,1 %
59,0 %
7,3 %
−2,0 %
2.95
1.87
| % | |
|---|---|
| Plasma | 35% Devices, disposables, and software used by plasma centers to collect plasma efficiently and manage donor operations. |
| Blood Center | 23% Collection and processing systems for blood centers handling plasma, red cells, and platelets. |
| Hospital - Interventional Technologies | 22% Products used in interventional procedures, including vascular closure, sensor-guided technologies, and esophageal protection. |
| Hospital - Blood Management Technologies | 20% Products that help hospitals manage bleeding and blood use, including hemostasis, cell salvage, and transfusion management. |
Haemonetics sells primarily to healthcare and blood-collection institutions rather than individual patients...
- Plasma collection customersprimary
Biopharmaceutical plasma operators buy collection devices, disposables, and software to run donor centers efficiently and reliably.
- Blood centersprimary
Independent and institutional blood centers buy collection and processing systems for plasma, red cells, and platelets.
- Hospitalsprimary
Hospitals buy interventional and blood management products to support procedures, reduce blood loss, and improve workflow.
- Group purchasing organizationssecondary
GPOs influence purchasing decisions and contract access for hospital products.
- National health organizationssecondary
Public health systems and agencies buy blood collection solutions through tenders and centralized procurement.
Haemonetics generates most of its revenue in the United States, with the remainder coming from international markets...
- •United States is the largest revenue market at 74.3% of fiscal 2025 sales
- •Europe contributed 12.9% of fiscal 2025 revenue
- •Japan contributed 4.6% of fiscal 2025 revenue
- •Rest of Asia contributed 6.8% of fiscal 2025 revenue
- •Sales span about 95-96 countries through direct and distributor channels
- •FX exposure is meaningful because international sales are local-currency based
Haemonetics is prioritizing the Plasma and Hospital segments, which management believes have the strongest growth...
01
Expand Plasma and Hospital franchisesmedium-term
Management sees these as the highest-growth businesses and the main drivers of long-term value.
02
Refocus Blood Center on targeted opportunitiesshort-term
Blood Center operates in more challenging markets, so resources are being concentrated on the most attractive niches.
03
Invest in product innovation and regulatory executionmedium-term
New products and approvals are needed to defend share and keep pace with clinical and technology changes.
04
Use capital allocation to support growth and dilution managementshort-term
Repurchases and disciplined investment help balance shareholder returns with funding for the business.
Haemonetics is exposed to customer concentration, especially in Plasma, where a small number of accounts drive a...
Regulatory and clinical adoption risk
Products require approvals and must keep pace with evolving clinical practice and standards.
- Scope
- All segments
- Materiality
- high
Competitive pressure
Large global competitors have substantial resources and similar product offerings, which can affect pricing and market share.
- Scope
- Plasma, Blood Center, Hospital
- Materiality
- high
Foreign exchange volatility
International sales are denominated in local currencies, especially yen, euro, and yuan, creating translation and transaction exposure.
- Scope
- Europe, Japan, Rest of Asia
- Materiality
- medium
Cybersecurity and data integrity
Medical devices and software handle sensitive patient and customer information and could be targeted by attackers.
- Scope
- Connected products and internal systems
- Materiality
- medium
Revenue recognition and variable consideration
Affects reported sales and gross margin
Inventory excess and obsolescence reserves
Affects cost of sales and operating profit
Goodwill and intangible asset impairment
Affects operating income and balance sheet carrying values
Foreign currency hedging
Affects reported earnings and cash flow volatility
HAEMONETICS CORP
HAE · Surgical & Medical Instruments & Apparatus
Haemonetics is a U.S.-based medical technology company that designs and sells systems used to collect, process, and manage blood and plasma.
CYTOKINETICS INC
CYTK · Pharmaceutical Preparations
Cytokinetics is a U.S.-based specialty biopharmaceutical company built around muscle biology and the mechanics of contractility.
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
LIFECORE BIOMEDICAL, INC. \DE\
LFCR · Pharmaceutical Preparations
Lifecore Biomedical is a U.S.-based contract development and manufacturing organization focused on complex sterile injectable products and pharmaceutical-grade hyaluronic acid (HA).
AETHLON MEDICAL INC
AEMD · Surgical & Medical Instruments & Apparatus
CorMedix Inc.
CRMD · Pharmaceutical Preparations
: 28.4.2026